Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RenovoRx, Inc. (RNXT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. RenovoRx is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform.
Through its SEC filings, RenovoRx reports financial results, commercialization progress for RenovoCath, and updates on its clinical development programs. For example, Form 8‑K filings have referenced quarterly financial press releases that discuss revenue from RenovoCath sales, expansion of cancer center customers, and advancement of the Phase III TIGeR‑PaC trial evaluating intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer.
Filings also describe capital markets activity. In a Form 8‑K dated November 14, 2025, RenovoRx reported entering into a Capital on Demand™ Sales Agreement with a sales agent, allowing the company to issue and sell shares of common stock in at‑the‑market offerings or negotiated transactions under an effective shelf registration statement on Form S‑3. Related exhibits include the sales agreement and a legal opinion on the validity of the shares.
On Stock Titan, users can review these filings alongside AI‑generated highlights that help explain key sections, such as risk factor updates, financing terms, and business strategy disclosures. Investors can also monitor current reports that incorporate press releases detailing clinical milestones, registry studies, Scientific Advisory Board changes, and commercialization strategy for RenovoCath and the TAMP platform.
In addition, this page is a starting point for tracking RenovoRx’s ongoing reporting obligations, including future quarterly and annual reports, as well as any additional Forms 8‑K that may discuss clinical trial developments, capital raises, or changes in governance.
RenovoRx, Inc. director Laurence J. Marton reported a non‑derivative transaction and a derivative grant on 10/01/2025. He was granted 47,640 stock option awards with an exercise price of $1.34, exercisable beginning 10/01/2025 and expiring 10/01/2035. The option shares vest in 12 equal monthly installments starting 11/01/2025. The Form 4 was signed and filed on 10/03/2025. The report lists Mr. Marton as a director and the filing indicates the options are held directly.
RenovoRx director Una S. Ryan was granted a stock option on 10/01/2025 to purchase 47,640 shares of common stock at an exercise price of $1.34 per share. The option vests in 12 equal monthly installments beginning 11/01/2025 and expires on 10/01/2035. Following the grant, Ms. Ryan directly beneficially owns 47,640 options. The Form 4 was signed on 10/02/2025 and shows the filing was made by a single reporting person.
Shaun Bagai, who serves as both Chief Executive Officer and a director of RenovoRx, Inc. (RNXT), reported two open-market purchases of the company's common stock in late August 2025. On 08/22/2025 he acquired 5,000 shares at $0.9495, increasing his beneficial holdings to 325,040 shares. On 08/25/2025 he purchased another 5,000 shares at $0.9098, bringing total reported holdings to 330,040 shares. The Form 4 was signed by Mr. Bagai on 08/26/2025 and expressly states these were open market purchases.
RenovoRx, Inc. filed a current report stating that on August 14, 2025 it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company also used the press release to share updates on its clinical trial and commercialization strategy.
The press release is included as Exhibit 99.1 to the report and is incorporated by reference, meaning the detailed financial figures and strategic updates are provided in that exhibit rather than in the body of the report.
AWM Investment Company, Inc. reports beneficial ownership of 1,870,225 shares of RenovoRx common stock, representing 5.1% of the class. AWM is the investment adviser to three funds that together hold the shares and, as adviser, holds sole voting and dispositive power over the position. The reported holdings break down to 1,064,431 shares held by Special Situations Fund III QP, 296,698 shares held by Special Situations Cayman Fund, and 509,096 shares held by Special Situations Life Sciences Fund.
The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.